Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRG NASDAQ:BTAI NASDAQ:CRVO NASDAQ:HOWL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$0.66+1.6%$0.80$0.43▼$2.04$8.23M-31.48 million shs286,798 shsBTAIBioXcel Therapeutics$1.22-1.6%$1.34$1.01▼$8.08$33.57M0.31932,054 shs563,694 shsCRVOCervoMed$3.95+3.9%$4.03$3.51▼$13.13$35.18M-0.6339,662 shs60,088 shsHOWLWerewolf Therapeutics$0.68+9.7%$0.81$0.53▼$2.38$30.13M0.41281,342 shs2.43 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI0.00%-7.32%-39.28%+13.80%-62.01%BTAIBioXcel Therapeutics0.00%+0.81%+12.73%-17.33%-18.95%CRVOCervoMed0.00%+2.98%-5.94%-28.44%-57.06%HOWLWerewolf Therapeutics0.00%-13.84%-37.02%+1.27%-32.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$0.66+1.6%$0.80$0.43▼$2.04$8.23M-31.48 million shs286,798 shsBTAIBioXcel Therapeutics$1.22-1.6%$1.34$1.01▼$8.08$33.57M0.31932,054 shs563,694 shsCRVOCervoMed$3.95+3.9%$4.03$3.51▼$13.13$35.18M-0.6339,662 shs60,088 shsHOWLWerewolf Therapeutics$0.68+9.7%$0.81$0.53▼$2.38$30.13M0.41281,342 shs2.43 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI0.00%-7.32%-39.28%+13.80%-62.01%BTAIBioXcel Therapeutics0.00%+0.81%+12.73%-17.33%-18.95%CRVOCervoMed0.00%+2.98%-5.94%-28.44%-57.06%HOWLWerewolf Therapeutics0.00%-13.84%-37.02%+1.27%-32.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 1.00SellN/AN/ABTAIBioXcel Therapeutics 2.25Hold$11.00801.64% UpsideCRVOCervoMed 2.63Moderate Buy$23.00482.28% UpsideHOWLWerewolf Therapeutics 2.14Hold$3.75451.47% UpsideCurrent Analyst Ratings BreakdownLatest BFRG, CRVO, BTAI, and HOWL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2026CRVOCervoMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/22/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.004/20/2026BFRGBullfrog AI Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRVOCervoMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.004/2/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $5.003/18/2026CRVOCervoMed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $11.003/18/2026CRVOCervoMed Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.003/17/2026BTAIBioXcel Therapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$17.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$120K69.63N/AN/A$0.19 per share3.47BTAIBioXcel Therapeutics$640K51.62N/AN/A($4.37) per share-0.28CRVOCervoMed$4.01M9.12N/AN/A$1.97 per share2.01HOWLWerewolf TherapeuticsN/AN/AN/AN/A$0.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$6.50M-$0.63N/AN/AN/AN/A-273.24%-208.55%5/12/2026 (Estimated)BTAIBioXcel Therapeutics-$69.90M-$6.71N/AN/AN/A-10,887.38%N/A-181.48%5/11/2026 (Estimated)CRVOCervoMed-$26.97M-$2.98N/AN/AN/A-672.80%-96.04%-82.88%5/11/2026 (Estimated)HOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-176.04%-69.87%N/ALatest BFRG, CRVO, BTAI, and HOWL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325N/AN/AN/A$0.39 millionN/A5/11/2026Q1 2026CRVOCervoMed-$0.7875N/AN/AN/A$0.07 millionN/A5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/27/2026Q4 2025BTAIBioXcel Therapeutics-$0.58-$0.58N/A$0.65$0.15 millionN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/A3/19/2026Q4 2025BFRGBullfrog AIN/A-$0.12N/A-$0.12N/AN/A3/13/2026Q4 2025CRVOCervoMed-$0.79-$0.88-$0.09-$0.88$0.84 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A3.853.85BTAIBioXcel TherapeuticsN/A0.830.82CRVOCervoMedN/A4.914.91HOWLWerewolf TherapeuticsN/A1.621.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%BTAIBioXcel Therapeutics30.68%CRVOCervoMed25.15%HOWLWerewolf Therapeutics64.84%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI25.16%BTAIBioXcel Therapeutics3.70%CRVOCervoMed35.40%HOWLWerewolf Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI412.66 million9.48 millionNot OptionableBTAIBioXcel Therapeutics9027.08 million26.07 millionNo DataCRVOCervoMed49.26 million5.98 millionNot OptionableHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableBFRG, CRVO, BTAI, and HOWL HeadlinesRecent News About These CompaniesWerewolf Therapeutics (NASDAQ:HOWL) Rating Lowered to Sell at Wall Street ZenMay 9 at 2:57 AM | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 79,086 SharesMay 8 at 8:01 AM | insidertrades.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Rating of "Hold" from AnalystsMay 8 at 3:57 AM | americanbankingnews.comWerewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7 at 4:05 PM | globenewswire.comLuke Evnin Sells 58,394 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockMay 6 at 5:56 AM | americanbankingnews.comLuke Evnin Sells 47,963 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockMay 6 at 5:56 AM | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) Director Sells $34,533.36 in StockMay 5, 2026 | insidertrades.comWerewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 168,262 SharesMay 5, 2026 | americanbankingnews.comInsider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 56,559 Shares of StockApril 30, 2026 | insidertrades.comWerewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14April 28, 2026 | msn.comWerewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid PriceMarch 28, 2026 | tipranks.comWerewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38March 27, 2026 | msn.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 27, 2026 | globenewswire.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Announces Plan to Explore Strategic AlternativesFebruary 26, 2026 | finanznachrichten.deWerewolf Therapeutics Announces Plan to Explore Strategic AlternativesFebruary 24, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Medtronic (MDT), Elanco Animal Health (ELAN) and Werewolf Therapeutics (HOWL)February 18, 2026 | theglobeandmail.comWerewolf Therapeutics stock falls after announcing 64% workforce reductionFebruary 13, 2026 | investing.comWerewolf Therapeutics stock rises over 5% after hours on workforce reduction, including executivesFebruary 13, 2026 | msn.comWerewolf Therapeutics Receives Nasdaq Minimum Bid Price NoticeFebruary 6, 2026 | tipranks.comLuke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockJanuary 21, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFRG, CRVO, BTAI, and HOWL Company DescriptionsBullfrog AI NASDAQ:BFRG$0.66 +0.01 (+1.59%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.66 +0.00 (+0.61%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.BioXcel Therapeutics NASDAQ:BTAI$1.22 -0.02 (-1.61%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.22 0.00 (-0.33%) As of 05/8/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.CervoMed NASDAQ:CRVO$3.95 +0.15 (+3.95%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.98 +0.03 (+0.76%) As of 05/8/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Werewolf Therapeutics NASDAQ:HOWL$0.68 +0.06 (+9.68%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.68 +0.01 (+0.74%) As of 05/8/2026 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
